ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Single Dose Rituximab and Anti-Thymocyte Globulin (ATG) Induction in Hypersensitized Kidney Transplant Recipients

A. X. Wang, U. Wang, S. Busque, C. R. Lenihan

Stanford University School of Medicine, Stanford, CA

Meeting: 2020 American Transplant Congress

Abstract number: A-007

Keywords: Graft survival, HLA antibodies, Kidney transplantation, Rejection

Session Information

Session Name: Poster Session A: Kidney Immunosuppression: Induction Therapy

Session Type: Poster Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

*Purpose: Hypersensitized kidney transplant recipients (calculated panel reactive antibody (cPRA) ≥98%) may represent a population at high risk of posttransplant immunologic events. While access to transplantation for this group has increased with the new kidney allocation system, their optimal induction regimen remains uncertain. At our center we administer a single dose of rituximab in addition to ATG at induction in this high immunological risk cohort. The goal of this study was to compare the outcomes of patients receiving rituximab and ATG as induction, the majority of whom were hypersensitized, with highly sensitized patients (cPRA ≥80%) who received ATG alone.

*Methods: We abstracted clinical and laboratory data on adult patients with a pretransplant cPRA ≥80% who underwent kidney transplant at our institution between December 2014 and November 2018. All patients received a flow cross-match compatible graft. We excluded patients who underwent pretransplant desensitization or simultaneous multiorgan transplants. Baseline characteristics were abstracted by chart review. The exposure of interest was receipt of rituximab at induction. Examined 1-year posttransplant outcomes were 1) patient and death censored graft survival, 2) glomerular filtration rate (GFR), 3) de novo (dn) DSA formation, 4) biopsy proven T-cell or antibody mediated rejection, 5) the composite of dnDSA and rejection, and 6) BK viremia.

*Results: 57 patients received rituximab and ATG (Ritux) and 29 received ATG alone (Control). The Ritux group were (numerically) younger, more sensitized and received kidneys with a longer cold ischemia time and a lower kidney donor profile index. The majority of transplants were from deceased donors. ATG dose was similar and maintenance immunosuppression consisted of tacrolimus, mycophenolate mofetil, and prednisone for both groups. 1-year patient and death censored graft survival was similar for Ritux and Control (98% vs 100% and 96% vs 96%, respectively). 2 patients with primary graft non-function (1 in each group) and 1 patient who died early posttransplant (in Ritux) were excluded from the remaining outcome analyses which are summarized in Table 1.

*Conclusions: The addition of rituximab to ATG as induction for hypersensitized patients appears to be safe and is associated with excellent 1-year outcomes. We observed a numerically lower number of immunologic events during the first year post transplant in patients who received rituximab. Our observations warrant further evaluation of anti-B cell therapy induction for hypersensitized patients undergoing kidney transplant.

Table 1
1-Year Outcomes Ritux (n=55) Control (n=28) P Value
Mean GFR (ml/min) 68 +/- 23 65 +/-21 0.47
Rejection 5 (9%) 5 (18%) 0.29
De Novo DSA 7 (12%) 6 (21%) 0.35
De Novo DSA or Rejection 10 (18%) 10 (36%) 0.10
BK Viremia 13 (23%) 5 (18%) 0.78
  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Wang AX, Wang U, Busque S, Lenihan CR. Single Dose Rituximab and Anti-Thymocyte Globulin (ATG) Induction in Hypersensitized Kidney Transplant Recipients [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/single-dose-rituximab-and-anti-thymocyte-globulin-atg-induction-in-hypersensitized-kidney-transplant-recipients/. Accessed May 11, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences